Liposomal simvastatin attenuates neointimal hyperplasia in rats

Area of Science:

• Cardiovascular Research
• Pharmacology
• Immunology

Background:

• Monocytes, macrophages, and inflammation are critical in neointimal proliferation and restenosis.
• Developing strategies to inhibit neointima formation is crucial for managing vascular diseases.

Purpose of the Study:

• To evaluate the efficacy of systemic, transient monocyte depletion using simvastatin liposomes for inhibiting neointima formation.
• To assess the potency of simvastatin liposomes compared to free simvastatin in inhibiting monocyte/macrophage proliferation.

Main Methods:

• Balloon-injured rat carotid artery model (n=30) treated with simvastatin liposomes, free simvastatin, or saline.
• Morphometric analysis to determine stenosis and neointima to media ratio (N/M) at 14 days.
• Flow cytometry for assessing circulating monocyte depletion and MTT assay for cell proliferation inhibition.

Main Results:

• Simvastatin liposomes were 1.5-2 times more potent than free simvastatin in suppressing monocyte/macrophage proliferation in vitro.
• IV injection of liposomal simvastatin induced a transient, prolonged depletion of circulating monocytes compared to free simvastatin.
• Liposomal simvastatin significantly suppressed neointimal growth, with N/M of 0.90 +/- 0.12 versus 1.56 +/- 0.16 in controls.

Conclusions:

• A single systemic administration of liposomal simvastatin effectively suppresses neointimal formation in a rat restenosis model.
• The observed inhibition is mediated by partial and transient depletion of circulating monocytes.
• Simvastatin liposomes represent a promising therapeutic approach for preventing restenosis.